Literature Review on the Immunogenicity of Herpes Zoster Vaccines (English, HTML)

View metadata and access the original English HTML file: Literature Review on the Immunogenicity of Herpes Zoster Vaccines.

Format

HTML

Access

file-only

Publisher-reported update

2019-04-25

Herpes zoster is an acute viral infection caused by reactivation of varicella-zoster virus (VZV). LZV, a live, attenuated vaccine for zoster has been available in Canada for many years. A new subunit recombinant zoster vaccine (RZV) named Shingrix was approved in Canada in October 2017. This zoster vaccine immunogenicity review was done to have a comprehensive understanding of the immunogenicity of both live and subunit vaccines.

Access original file